Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021

On October 28, 2021 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported that it will report the company’s third quarter 2021 financial results on Thursday, November 4, 2021 after the close of U.S. financial markets (Press release, Aligos Therapeutics, OCT 28, 2021, View Source [SID1234592165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Susan G. Komen Maximizes Breast Cancer Donor Dollars by Going Fully Remote with RingCentral Cloud Communications

On October 28, 2021 RingCentral, Inc. (NYSE: RNG), a leading provider of global enterprise cloud communications, video meetings, collaboration, and contact center solutions, reported that Susan G Komen, the world’s leading breast cancer organization, has turned to RingCentral MVP (Message Video Phone) to drive business communications across its entire operations (Press release, Susan G Komen, OCT 28, 2021, View Source [SID1234592161]). Since implementing RingCentral, Susan G. Komen has shifted its workforce to be fully remote, enabling employees to work from anywhere. The company has also ceased outsourcing its call center by deploying RingCentral Contact Center, bringing their helpline in-house. With these combined savings, the non profit organization is able to become more operationally efficient and dedicate more funds in support of its mission programming, such as advocacy, research, patient care, and support.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Susan G. Komen has invested more than $3 billion in groundbreaking research, community health outreach, advocacy, and programs in more than 60 countries since its founding in 1982, which is funded by donations from organizations and individuals—many of them pledged over the phone. For that reason, the nonprofit organization needed a more reliable communications solution as its previous on-premise communications system caused frequent outages, which meant a loss of potential donor funding. Additionally, the lack of mobility from their previous phone system prevented them from being able to implement a fully remote workforce.

"RingCentral gives us so much mobility and freedom. If I’m on a call or a RingCentral Video meeting on my laptop, and I need to run an errand, I can just switch the call to my mobile phone and head out. It’s fantastic for keeping us all productive and connected without tying us to our desks—or tying us anywhere for that matter," said Carlos Soto, hosted system administrator for Susan G. Komen. "The best part of being able to go 100% remote is that we can better invest that money into furthering our fight against breast cancer. I’ve never seen a more win-win situation for our organization."

Upon rolling out RingCentral Contact Center as its new customer support solution, support teams are improving many aspects of Komen’s operations and are now able to offer an elevated level of service. For example, Komen now has the capability to escalate a call with RingCentral’s three-way functionality to dial in a supervisor or emergency services if a patient exhibits the potential for self-harm. Having this solution in place for higher intensity calls brings their team confidence and peace of mind. To further assist the Helpline Specialists’ daily operations, the organization is using RingCentral’s out of the box integration with Salesforce. The integration enables its agents to easily take notes during a call and not have to re-enter the data. Those notes go straight into that caller’s Salesforce profile, where the next agent can see them, offering continuity and a more personalized level of service for future calls.

"It is so humbling and inspiring to see organizations like Susan G. Komen change the world for the better using our solutions," said Faiza Hughell, chief customer officer for RingCentral. "Empowering teams to keep doing the great work they do is our ultimate goal. Yes, the integrations we’ve built into our tools make things more efficient for support agents. However, they’ve let us know that the best part about capabilities like these is that for a person going through something as challenging as breast cancer, not having to retell their story each time makes for a much more comfortable experience."

Hexagon Interim Report 1 January – 30 September 2021

On October 28, 2021 Hexagon Bio reported that (Press release, Hexagon Bio, OCT 28, 2021, View Source;30-september-2021-301410679.html [SID1234592159])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third quarter 2021

Net sales increased by 15 per cent to 1,077.2 MEUR (939.9). Using fixed exchange rates and a comparable group structure (organic growth), net sales increased by 10 per cent
Adjusted operating earnings (EBIT1) increased by 19 per cent to 296.8 MEUR (250.1
Earnings before taxes, excluding adjustments, amounted to 290.5 MEUR (242.2)
Net earnings, excluding adjustments, amounted to 238.3 MEUR (198.6)
Earnings per share, excluding adjustments, amounted to 0.09 EUR (0.08)
Operating cash flow decreased to 179.6 MEUR (191.2)
For further information, please contact:

Maria Luthström, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, [email protected]

This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 28 October 2021.

This information was brought to you by Cision View Source

View Source;30-september-2021,c3441913

BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer

On October 28, 2021 BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, reported the appointment of Philippe Drouet as President and Chief Executive Officer of BioTheryX (Press release, BioTheryX, OCT 28, 2021, View Source [SID1234592158]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Philippe is an extremely talented biopharma executive with more than two decades of global experience in commercializing blockbuster oncology therapeutics. He has worked to advance products through clinical development, successfully launched them, and most importantly made them available to patients. His proven track record in building effective high performing teams will position us well to advance our pipeline of protein degraders and modulators to create life-saving medicines for patients," said David Stirling, Ph.D., Executive Chairman of BioTheryX. "The Board and I welcome him as CEO, and we are excited to have him lead our company as we build on our expertise in protein modulation-based drug development."

Prior to joining BioTheryX, Mr. Drouet served as Chief Commercial Officer at CRISPR Therapeutics where he shaped the strategy for the launch of the company’s first allogeneic CAR-T therapies and helped lead the clinical development strategy for the company’s phase I clinical assets. Previously, Philippe served as Senior Vice President, Global Oncology at Merck & Co. where he launched and commercialized Keytruda, drove substantial global oncology revenue and built and led the company’s Global Oncology Marketing, Access and Pricing organization. Prior to that, he served as President of Hospira’s U.S. division before Hospira’s acquisition by Pfizer in 2015. Philippe also held roles of increasing responsibility at Novartis Pharmaceutical Corporation, including Vice President U.S. Hematology, General Manager Oncology in Turkey, Global Brand Leader for Gleevec and Head of Oncology Marketing in Canada. Philippe received an MBA from INSEAD in France and a Master of Science and Bachelor in Chemical Engineering from McGill University, Canada.

"I am excited to join BioTheryX and lead the company through its next stage of rapid growth as it expands its programs in the fast-paced category of protein degradation," said Mr. Drouet. "BioTheryX has built one of the leading scientific teams and most promising pipelines in the protein degradation space. I look forward to working alongside this outstanding team to build our clinical-stage program for liquid and solid tumors and develop first-in-class therapies in areas of high unmet medical need in oncology and other diseases."

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

On October 28, 2021 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that the company will host a conference call and live webcast on Wednesday, November 3, 2021 at 4:15 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights (Press release, Heron Therapeutics, OCT 28, 2021, View Source [SID1234592157]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call can be accessed by dialing 877-311-5906 for domestic callers and 281-241-6150 for international callers. Please provide the operator with the passcode 7242566 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.